PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Major Depressive Disorder

Psychiatric Times.
PODCAST 

New Medication Strategies for Non-responsive Depressed Patients

By Gerard Sanacora, MD, PhD | July 17, 2012

Dr Sancora discusses a novel class of drugs for depressed patients

Although there have been significant advances in the treatment of mood disorders, many limitations of current strategies remain—and a large proportion of patients never attain complete remission of symptoms.

A series of studies completed over the past 12 years suggest that a novel class of drugs that directly target the glutamatergic neurotransmitter system may produce rapid and robust antidepressant effects in patients who had previously not responded to the standard monoaminergic antidepressant medications.

(MORE: New Claims and Findings for Ketamine in Severe Depression)

In this companion podcast to his article, “Ketamine Induced Optimism,” Gerard Sanacora, MD, PhD, Professor of Psychiatry at the Yale University School of Medicine and Director of the Yale Depression Research Program in New Haven, Connecticut, discusses early-phase clinical studies that provide strong evidence that this novel class of drugs may advance our ability to treat mood disorders.

Novel Drugs for Mood Disorders

Novel Drugs for Mood Disorders

iTunes Subscribe to our podcasts

 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by mark holscher | August 22, 2012 7:54 AM EDT

i read an article on a trial of N acetyl cystiene at a dose of 1000mg bid in TRD patients over one month who had a >90 % response rate in those patients that was noted to wane when the supplement was stopped.
i checked with a pharmD and others about the safety of this supplement. there did not seem to be any obvious risk or reported negative reactions to this supplement.
i decided to try it on one of my most difficult patients who was currently on parnate and depakote for TRD and BP2 for 40 years. he was started on 600mg once daily then increased to 600mg bid in 1 week. i did not tell him what to expect but to call with any problems and to report back to me in 2 weeks for follow up. '
he reports a gradual improvemnt in most of his sypmtoms over the two weeks. namely he has bettter mood a calmer affect clearer thinking and less social sensitivity. he is still on the same dose and continues to do well. since he has only been om this for one month it will be interesting to see if the benefits will continue at this dose.
if he continues to do well i plan to try this on some of my other more difficult trd patients.
what a blessing if this supplement costing 15.00 a month could truely relieve some of these patients disabling symptoms and improve their quality of life. thank you.

More like this

Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants

New Medication Strategies for Non-responsive Depressed Patients

Ketamine, Cum Grano Salis

New Claims and Findings for Ketamine in Severe Depression






 
RELATED TOPICS

Bipolar disorder
Depressive disorders
Dysthymia
Mood disorders
Psychotic affective disorders
Major depressive disorder
Suicide prevention and assessment

 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Will Your Clinical Records Support You in Court?
  • Refinements in ECT Techniques
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Grief and Depression: The Sages Knew the Difference
  • Psychiatry and the Myth of “Medicalization”
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • Experts Discuss Changes, Updates in DSM-5
  • New Insight Into the Neurobiology of Depression
  • Tie One On for Patients
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • Psychiatry and the Myth of “Medicalization”
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
CME
Get CME for reading Psychiatric Times articles
Mood Disorders
Anxiety Disorders
Sleep Disorders
Psychopharmacology
Schizophrenia-Psychotic disorders
Cognitive Disorders
Substance Abuse
Medical Comorbidities
More Psychiatry CME


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Mdd
Evidence on Mdd
Guidelines on Mdd
Patient Education on Mdd
Clinical Trials on Mdd
Practical Articles on Mdd
Research and Reviews on Mdd
All "Mdd" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy